X0306 4 2021-04-15 1 0000203527 VARIAN MEDICAL SYSTEMS INC VAR 0001753950 Toth Christopher A. C/O VARIAN MEDICAL SYSTEMS, INC. 3100 HANSEN WAY M/S E327 PALO ALTO CA 94304 1 SVP and Pres. Oncology Systems Common Stock 2021-04-15 4 D 0 15418 D 0 D Restricted Stock Units 2021-04-15 4 D 0 633 D Common Stock 633 0 D Restricted Stock Units 2021-04-15 4 D 0 1816 D Common Stock 1816 0 D Performance Shares 2021-04-15 4 D 0 6415 D Common Stock 6415 0 D Performance Shares 2021-04-15 4 D 0 8437 D Common Stock 8437 0 D Amount of securities disposed of reflect 196 shares purchased on April 8, 2021 under the Varian Medical Systems, Inc. Employee Stock Purchase Plan and a reduction of 8 shares as a result of a tax correction for the February 16, 2021 RSU vesting. Disposed of pursuant to merger agreement (the "Merger Agreement") between issuer and Siemens Healthineers I GmbH and certain other parties in exchange for a cash payment of $177.50 per share of common stock. Each restricted stock unit represents a contingent right to receive one share of VAR common stock. Pursuant to the Merger Agreement, these restricted stock units, which provided for vesting in three equal annual installments beginning February 14, 2020, were cancelled in exchange for a cash payment of $177.50 per unvested share of underlying common stock. Pursuant to the Merger Agreement, these restricted stock units, which provided for vesting in three equal annual installments beginning February 15, 2021, were cancelled in exchange for a cash payment of $177.50 per unvested share of underlying common stock. Each performance stock unit represents a contingent right to receive one share of VAR common stock. Pursuant to the Merger Agreement, these performance stock units, which were granted November 15, 2018, were cancelled in exchange for a cash payment of $177.50 per share of underlying common stock and applicable performance conditions were deemed to be achieved at the target performance level. Pursuant to the Merger Agreement, these performance stock units, which were granted November 21, 2019, were cancelled in exchange for a cash payment of $177.50 per share of underlying common stock and applicable performance conditions were deemed to be achieved at the target performance level. /s/ Magnus Momsen, attorney-in-fact 2021-04-16